ICSS has approved of Cell Surgical Network (CSN) and StemImmune Corp.’s cancer study for treating patients with advanced solid tumors. By combining autologous adipose derived stromal vascular fraction with ACAM 2000 vaccine, CSN and StemImmune aspire to show the safety of this novel approach and eventually its effectiveness in providing medical assistance to late-stage cancer patients. For more information please visit: http://stemcellrevolution.com/
